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Motto: “I did have strange ideas during certain periods of time.”
John Nash
We discuss the possibility of multiple underlying etiologies of the condition currently labeled as schizophre-
nia. We support this hypothesis with a theoretical model of the prefrontal-limbic system. We show how
the dynamical behavior of this model depends on an entire set of physiological parameters, representing
synaptic strengths, vulnerability to stress-induced cortisol, dopamine regulation and rates of autoantibody
production. Malfunction of different such parameters produces similar outward dysregulation of the system,
which may readily lead to diagnosis difficulties in a clinician’s office. We further place this paradigm within
the contexts of pathophysiology and of antipsychotic pharmacology. We finally propose brain profiling as
the future quantitative diagnostic toolbox that agrees with a multiple etiologies hypothesis of schizophrenia.
1 Introduction
1.1 Schizophrenia. Disease or syndrome?
As defined today, schizophrenia is a serious chronic disorder, affecting about 1.1% of the population
(over 65 million people worldwide, according to NIMH statistics). It is a source of unrelenting
personal and social drama, and underlies debilitating problems from unemployment and long-time
hospitalization to suicide.
As much as it would be beneficial to understand this disease and eliminate the torment it
brings to human life, its cause is still unknown by research and its current treatment brings no
reliable cure. The definition of schizophrenia itself is elusive, having been somewhat fabricated by
science [14] — based on statistical behavior, rather than etiology — so as to somehow encompass
all the complexities of a syndrome otherwise intractable. Progress has been made in understanding
the effects of particular antipsychotics on some of the modules involved in the disease process, such
as the dopaminergic or serotonergic brain systems, but the drugs that are being used may still treat
the effects of the disease rather than its mysterious cause [28].
Indeed, as of today, the etiology of schizophrenia is still not understood. It clearly affects struc-
turally and functionally various cortical and subcortical regions involved in cognitive, emotional and
motivational aspects of behavior [34] [1] [59] [2]. However, it seems that the days when schizophre-
nia was labeled as “brain sickness” are over. Its disease process has been shown to have much more
extensive physiological effects, including endocrine [49] and autonomic [40] factors, and has been
correlated to a plethora of somatic abnormalities, affecting aspects as thorough as autoimmunity
mechanisms, and as simple as “eating your vitamins.”
In fact, “schizophrenia’s” heterogeneous set of symptoms (hallucinations, delusional beliefs,
thought disorder, emotional flattening, social withdrawal) is diverse enough to possibly represent a
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whole collection of diseases in their own right [8]. In addition, most of the illness’ signs and symp-
toms are not unique to schizophrenia and overlap with the symptoms of other mental conditions,
such as major depression, bipolar mania, or post-traumatic stress disorder. In this context, newer
research is gradually moving in the direction of altering the existing unreliable terminology, even
towards entirely replacing it by a physiology-based system, optimizing predictive power.
Altogether, the diversity in symptomatology and the intractability of the disease’s etiology
could in fact have a bona fide explanation: there are multiple etiologies of schizophrenia [11]. It
seems sensible to hypothesize that the cognitive and behavioral symptoms of schizophrenia are
perhaps a generic outward psychopathological manifestation – much like “heart condition” in the
somatic context – which could be produced and maintained by any of an entire collection of causes
and mechanisms. Each etiology, although producing similar symptoms, has however a different
prognosis and should have a different diagnosis and most certainly a different treatment. This is
why it is clinically important to make these distinctions, and to strive for a novel organization of
the psychiatric terminology (see Section 4.3).
1.2 Vulnerability and limbic dysregulation
Significant research over the past decade has isolated the amygdala, the hippocampus and parts of
the prefrontal cortex as the brain areas most relevant in the mechanisms of fear conditioning and
emotion processing.
It has been proposed that schizophrenic symptoms constitute an end-stage of a cyclic and
neurodegenerative process, in which a hereditary predisposition (“vulnerability” [42]) reduces the
individual psychological threshold towards stimuli [60], to the point where even minor daily stresses
will directly trigger psychotic experiences [41]. It has been further hypothesized and documented
that the critical element in the physiological realization of this degeneration is dysregulation of
limbic regions. Specifically, this manifests as an imbalance between the two components of a
feed-back loop: (1) the top-down control provided by the cortical systems over subcortical areas
involved in emotion and (2) the control of neuromodulatory systems that in turn affect the cortex.
For example, one possible view involves the ability of the hippocampus and prefrontal cortex to
contextualize and inhibit activation of the amygdala, the excitatory module [58], which in turn
drives the dopaminergic system. Outputs of the dopamine system modulate processing in the
hippocampus and PFC, thus closing the feed-back cycle (see Section 2). In this context, it is
perhaps not surprising that schizophrenia has remained hard to understand, as a system governed
by complex limbic interactions.
One line of current thinking is that this vulnerability to stress in schizophrenia is based on
a pre-existing prefrontal-limbic deficit [38] [47] [63]. More precisely, an impairment in hippocam-
pal/prefrontal function may lead to decreased inhibition of the amygdala and subsequent higher
arousal levels, even under minor stress. Through the hypothalamo-pituitary axis, the fear reaction
triggers autonomic and endocrine effects [35], in particular increased cortisol levels [54]. These
produce brain neurotoxicity [67] and further hippocampus damage [45], at the level of neurogene-
sis [26] [70] and of hippocampal–PFC synaptic transmission [9]. This is possibly one of the main
degenerative cycles in schizophrenia, which the author has discussed in previous work [48].
This cortisol neurotoxicity hypothesis is gradually gaining ground in current approaches to
mental pathology [66]. However, other mechanisms of limbic vulnerability have been proposed
by biological and clinical studies, whose bases do not necessarily reside within the physiology of
the brain. The limbic dysregulation (and subsequent outward psychosis) could be the result of
a multitude of causes, including genetic confounds, drug abuse, brain trauma, or even lack of
proper minerals from food (such as Vitamin B12 and folate [44] [23]). These factors can all work
towards weakening the limbic parameters to a level which places the system in a mode of enhanced
vulnerability to environmental pressure.
One of the better known such factors is autoimmunity (i.e. the inability of the body to suppress
production of antibodies aimed against its own structures). In this paper, we extend our previous
model of limbic vulnerability to include the effects of autoimmunity on the prefrontal-limbic sys-
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tem. After a short introduction on autoimmunity and psychiatric manifestations of autoimmune
conditions, we organize the rest of the paper as follows.
Section 2 describes the brain pathways and physiological mechanisms included in our paradigm,
and constructs the mathematical model. Section 3 illustrates, using MATLAB simulations, the
behavior of the model and its evolution in a few cases of interest. Section 4 relates this mathematical
behavior with the brain pathophysiology, and places it within the context of identifying different
etiologies for schizophrenia. Finally, Section 5 takes a glimpse into a possible future of psychiatric
diagnoses and treatment, if based on such temporal architecture modeling.
1.3 Autoimmunity — a road to psychosis
Basic and clinical experimental data has correlated autoimmune dysregulation to autward psy-
chosis. To fix our ideas, we will consider a standard example of a systemic autoimmune condition:
Systemic Lupus Erithematosus (SLE). It affects mainly young people by attacking indiscriminately
— with sudden, seemingly unpredictable flares — multiple organ systems, among which the brain.
Neuropsychiatric manifestations have a prevalence of up to 75 − 90% in SLE. However, despite
this strong correlation between autoimmune deficiencies and central neurological and psychiatric
problems, studies have not consistently proved any causality between the two phenomena, in ei-
ther direction. It is quite possible that the disease system contains bilateral interactions between
the immunity and central nervous subunits [5], as well as other external modulations (e.g., from
external stress [21] and the subsequent hypercortisolemia).
Although not unexpected, this complexity complicates a possible global analysis that would lead
to better understanding of the system. On the other hand, this understanding is clinically very
important. SLE symptoms — including depression, anxiety, psychosis, mania, cognitive dysfunction
— have been more than once “misdiagnosed” as schizophrenia in a psychiatrist’s office [3]. Clearly, it
is of crucial importance to avoid confusions, since in such a case a treatment trial should be planned
to match the physiological autoimmune condition, not just to alleviate the outward psychiatric
symptoms with antipsychotic medication [10].
As we have already mentioned, in autoimmune conditions such as SLE, the body produces
autoantibodies, i.e., antibodies to its own tissues. It is thought that most forms of autoimmunity
start up for no obvious reason, apparently by chance [15], with the production of an autoantibody
which, through a vicious cycle, stimulates its own production. One such example in SLE is the
autoantibody that targets a complement system molecule called C1q, causing decreased apoptotic
cell clearance, and thus facilitating more autoantibody production [55]. This and other complexities
suggest that lupus may be driven by a whole series of connected such antibody cycles, possibly
themselves generated by low C1q levels.
Among the variety of autoantibodies produced in SLE, some are particularly dangerous to the
central nervous system (CNS). Several studies have focused on isolating antibodies that target
specific brain structures, such as neuronal membrane antigens, ribosomal proteins or endothelial
surfaces. For example: anti-cardiolipin (an antiphospholipid) produces prothrombotic effects which
lead to ischemia and infarction and eventually to neuronal death [22]. Aditionally, anti-endothelial
antibodies [64] contribute to the general damage of vessel wall endothelium, thus lowering the
blood-brain barrier and allowing easier penetration of other antibodies or neurotoxic factors from
the blood into the CNS. Although most molecular mechanisms of CNS-directed autoimmunity are
still under investigation, it is believed that, rather than irreversible cell death, some anti-neuronal
antibodies [7] may have more transient detrimental effects on neural function. These effects include
signaling, myelination [31] [27], synaptic plasticity, neurotransmitters [39] and receptor dynamics.
The antineuronal antibodies most typical to lupus are anti-DNA antibodies, which act at the
level of NMDA receptors [43]. Abnormal synaptic remodeling due to dysregulated NMDA receptor
trafficking provides a very plausible mechanism for neuropsychiatric disorders such as Alzheimer’s
disease, cocaine addiction and schizophrenia [72] [33]. This is why in our model the effects of
autoimmunity will be introduced at the synaptic level, as an impairment in transmission in certain
neural pathways. Since our study is concerned with the brain dynamics between prefrontal and
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limbic regions of interest, understanding if and how they are targeted by autoimmunity is very
useful. In this sense, we use recent results on the possible selective production of antibodies against
specific brain regions [51]. Indeed, serum antibodies have been reported against a few regions,
including the hippocampus [20] [29] [71], the amygdala [25] and frontal cortex [25].
Finally, it is very important to notice in our context that the classical SLE treatment plan
is based on corticosteroid medication, due to its immunosuppressive effects [13]. Severe diffuse
CNS manifestations, such as acute confusional state, generalized seizures, mood disorders and
psychosis, generally require immediate corticosteroid administration [53], and psychiatric symptoms
tend to resolve within three weeks of treatment. On the other hand, hypercortesolemia (possibly
through the neurotoxic effects on the prefrontal/hippocampal inhibitory module discussed earlier
in the section) could itself cause a variety of psychiatric syndromes such as mania, depression,
psychosis, anxiety, dellirium [10]. It seems therefore crucial that a medication plan be finely tuned
to correspond to the particular needs of each individual patient, since an overdose could lead to
exactly the undesired symptoms that it aims to cure. This emphasizes yet again the importance of
a sustainable and detailed enough diagnosis that would permit a correct treatment evaluation.
In the Discussion section, we will further interpret the potential interference of corticosteroid
medication with the central and endocrine mechanisms that are beleived to be responsible for
psychosis in schizophrenia.
2 The construction of the mathematical model
Figure 1: Simplified schema of the prefrontal-limbic pathways incorporated in our model, as de-
scribed in Section 2. mPFC = medial prefrontal cortex; NAc = nucleus accumbens; VTA = ventral
tegmental area; CA1 = Cornu Ammonis 1; vSub = ventral subiculum; “+” stands for excitatory
pathway, “−” for inhibitory pathway and “DA” for dopamine modulated pathway.
In our previous work [48], we have related schizophrenia to a vulnerability of the inhibitory
limbic/prefrontal module reinforced by neurotoxic effects of stress-induced hypercortisolemia. In
this section we will describe a mathematical model which, while still based on this limbic vulnera-
bility, will also reflect some of the more subtle physiological mechanisms discussed in the previous
sections. If constructed correctly, this extended model will address in a biologically plausible way
not only the underpinnings of fear conditioning and extinction, but also the impact of autoimmu-
nity on limbic processing and the effects of corticosteroids and antipsychotic medication which are
generally prescribed for SLE and schizophrenia.
We start with a simpler case, not including the effects of autoimmunity. First, we define our
terminology and notations, and we elaborate the simplified model. We then continue by explaining
the underlying set of pathways and physiological rules on which we based our paradigm.
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We represent the time activations of the amygdala, the hippocampus and the prefrontal cortex
as three distinct variables a, p and h, while a fourth variable δ stands for the activation of the
dopamine system, controlled via the nucleus accumbens (NAc) and the ventral tegmental area
(VTA). The interactions between these variables are quantified by a collection of real positive
parameters I,M, µ1, µ2, k1, k2, k3, γ1, γ2, a1, a2, α, β, ξ1, ξ2 and ξ3 as follows:
a˙ = −µ1a− k1p− γ1h+ I
p˙ = k2a− µ2(1 + δ)p+ γ2
a1C + 1
h
h˙ = k3(1 + δ2)p− a2C
δ˙ = −ξ1(1 + δ)a+ ξ2(1 + δ)p+ ξ3(1 + δ)h
Aside from a self-modulatory inhibition −µ1a, the amygdala receives a constant environmental
input I via thalamic pathways, and provides excitatory outputs k2a to the prefrontal cortex [58].
Newer findings indicate that BLA receives a stress-responsive dopamine (DA) projection from
the ventral tegmental area (VTA) [36], and itself dampens the DA response in the NAc [61].
Outputs from the amygdala, through the hypothalamo-pituitary axis, also provide inputs for the
endocrine and autonomic nervous systems, controlling indirectly the cortisol production in response
to stress [54].
In our model, we express the amygdala-controlled cortisol as a function f(α, a) = α
ea
ea + 1
, so
that any activation a of the amygdala produces an increase from zero in the production of cortisol.
This increase cannot exceed a saturation level α, independently of the level of stress. The stress-
induced cortisol, together with corticosteroid-based medication M , determine the levels of blood
cortisol C = M + f(α, a), whose known neurotoxic effects influence the structure and activity of
the hippocampal/prefrontal inhibitory unit, as shown below.
The prefrontal cortex receives excitatory inputs k2a from the amygdala and strong excitatory
hippocampal projections γ2h to the prefrontal prelimbic and infralimbic regions. The synaptic
efficacy of this pathway is impaired by increased levels of blood cortisol; to account for this, we
have adjusted the corresponding term to
γ2
a2C + 1
h. More recent research reveals the importance
of dopaminergic modulation of the mPFC inhibition via GABA interneurons. Projections from
the mPFC to the VTA [6], together with a reciprocal dopaminergic pathway from the VTA to
the mPFC, comprise the mesocortical circuit [24] [68]. More precisely, the glutamate-containing
pyramidal neurons which are the target of VTA DA terminals make synapses on non-pyramidal
GABAergic inhibitory interneurons in the mPFC [24] [56]. Interneuron inhibition in mPFC has
been related to schizophrenia in recent studies [65]. We have expressed this dopamine modulated
self-inhibition as the term −µ2(1 + δ)p.
The hippocampus directly inhibits activation of the amygdala (−γ1h) and reinforces activity
in the prefrontal cortex, supporting the process of memory formation and centralization (γ2h).
In this process, the contribution of the DA system is again very important. The CA1/ventral
subiculum (vSub) send dense glutametergic projections to the NAc, which are under a powerful
DA neuromodulatory influence exerted by the VTA [19]. NAc directly projects to the VTA, and, in
turn, the dopaminergic input from the VTA is knwon to enhance long term potentiation in CA1 [36].
In addition, the hippocampus receives modulations from both the amygdala (cortisol-neurotoxic
inhibition −γC) and the mPFC (excitatory modulation throught multineuronal etnorhinal and
perirhinal pathways k3(1 + δ2)p, where the factor (1 + δ2) signifies the dopamine-modulated LTP
enhancement in CA1).
The dopamine system receives dopamine-modulated inputs from all three prefrontal-limbic ar-
eas, as shown by the fourth equation, in which the strengths of these modulations are proportional
to the parameters ξ1, ξ2 and ξ3.
As mentioned in the introduction, the large variety of autoantibodies and the complexity of their
effects are not very well differentiated by research, and are therefore difficult to encompass in all
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detail. So, in order to conveniently extend our model to encompass autoimmunity, we focused on its
effects at the level of amygdalar and hippocampal synaptic transmission, since these structures and
areas have been particularly shown to be affected by autoimmunity in SLE. We consider the level
of anti-neuronal autoantibodies to be modeled by an exponential increase in time: B(t) = eβt/C .
Here β is the exponential growth rate that reflects the self-enforcing vicious cycle of autoantibody
production, and C is the blood level of cortisol, which slows down (without completely stopping)
this production. With these additions, the system becomes:
a˙ = −µ1a− k1p− γ1
eβt/C
h+ I
p˙ =
k2
eβt/C
a− µ2p+ γ2
eβt/C(a1C + 1)
h
h˙ = k3(1 + δ2)p− a2C
δ˙ = −ξ1(1 + δ)a+ ξ2(1 + δ)p+ ξ3(1 + δ)h
Notice that, through the parameters µ1, µ2, k1, k2, k3, γ1, γ2, ξ1, ξ2, ξ3 > 0, the brain
region interactions, represented by the linear terms of the system, reflect the excitatory/inhibitory
character described in Section 2.1. The finer and slower modulations due to the effects of cortisol,
dopamine or CNS antibodies are represented here as nonlinearities, consistent with our previous
work [48].
3 Analytical results and simulations
Generally, the mathematical analysis of such a system could be cumbersome, even intractible. Con-
sidering the large number of parameters that can be varied independently, we expect the behavior
of the system to change with these parameters’ variations and exhibit complex bifurcations at
particular critical values.
In future work, we plan to focus around such detailed analyses, and on numerical computation of
critical bifurcation parameters when theoretical approaches are not possible. However, the purpose
of this paper is not to build a complete mathematical analysis of the model we have constructed,
especially since the model itself is not uniquely defined physiologically (most pathways, modulations
and parameter values are still under investigation). We will instead adopt here a less precise, but
rather more descriptive approach, aimed at illustrating basic ideas, such as the possible multitude
of etiologies that underlie schizophrenic outward symtoms.
In this section, we fix a set of plausible initial states, and we simulate the time evolution of these
states under particular combinations of parameter values. Since we are mainly interested in the
levels of prefrontal-limbic activations over time, and since we had to pick a 3-dimensional subspace
for our graphic illustrations – we plotted all trajectories in the 3-dimensional phase-space (a, p, h).
We observe in particular how these trajectories distort as the parameters change in a controlled
way. Although we do not investigate analytically the phenomena that appear under deformations
of the system, the simulations suggest the presence of multiple Hopf and Bautin bifurcations as
parameters traverse certain tresholds.
3.1 Model behavior without autoimmunity
In our previous work, we have analyzed how the behavior of a two-dimensional prefrontal-limbic
system changes under particular changes of the system’s parameters. As a start, we wanted to verify
that this extended paradigm was indeed consistent with our prior modeling results. Therefore, we
first focused on investigating the behavior of the trajectories under perturbations of the amygdala
self-inhibition strength µ1 and of the prefrontal/hippocampal vulnerability to cortisol neurotoxiticy,
represented here by a1 and a2.
We gradually decreased the amygdala self-inhibition µ1, while keeping the other parameters
fixed. As expected, large enough values of µ1 forced the time-evolutions to converge to a steady
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Figure 2: The three panels show the evolution of the three fixed trajectories in the 3-dimensional
phase-subspace (a, p, h). We have fixed: µ2 = 2, k1 = 2, k2 = 2, k3 = 1, α1 = 1, a1 = a2 = 1,
ξ = 2, I = 1, α = 0 and M = 0 (i.e. no autoimmunity). A. µ1 = 1.4; the trajectories are attracted
to a point. B. µ1 = 1; the attractor is switching from a point to a cycle. C. µ1 = 0.21; the cycle
has disappeared and the trajectories are no longer attracted.
state. As we lowered µ1, we crossed a critical value where the trajectories seemed to stabilize to
a locally attracting cycle. For values lower than this critical value, the attractor was lost, and the
trajectories became more chaotic (see Figure 2).
A similar bifurcation appeared to manifest when varying the parameters a1 and a2. Indeed,
while for small values of these two parameters the system converged to a stable state, increases in
either one of the two values led to the shift of the attractor state to an attracting cycle, and then to
total loss of the local attractor, which caused the trajectories to be repelled away from the steady
state.
Figure 3: In all three panels, we fixed: µ1 = 2, µ2 = 2, k1 = 2, k2 = 2, k3 = 1, α1 = 1, ξ = 2,
I = 1, α = 0 and M = 0 (i.e., no autoimmunity). A. a1 = a2 = 1. The trajectories are attracted
to a point. B. a1 = 5 and a2 = 2. The trajectories are attracted to a cycle. C. a1 = 5, a2 = 2.64.
The trajectories are repelled.
Before bringing autoimmunity into the picture, one last interesting behavior we wanted to
understand was the effect of the dopamine levels / dopamine receptivity in the limbic and pre-
frontal modules of this model. As we increased the prefrontal-limbic modulation parameters of the
dopamine system from ξ1 = ξ2 = ξ3 = ξ = 2 to ξ1 = ξ2 = ξ3 = ξ = 2, the system became more
unstable, as shown in Figure 4. The Discussion section offers further interpretations of this loss of
stability and of its significance in the context of antipsychotic medication.
7
Figure 4: In all three panels, we fixed: µ1 = 1, µ2 = 2, k1 = 2, k2 = 2, k3 = 1, α1 = 1, a1 = a2 = 1,
I = 1, α = 0 and M = 0 (i.e. no autoimmunity). A. ξ = 2; the trajectories are attracted to a
point. B. ξ = 3; the trajectories are attracted to a cycle. C. ξ = 3.5; the trajectories are repelled.
3.2 Model behavior including autoimmunity
The synaptic impairment due to autoimmunity, as introduced in this model, depends directly on
two quantities: the exponential growth rate of antibody production β and the blood levels of cortisol
C, which acts as an immunosuppressor. Figures 5 and 6 illustrate how corticosteroid medication
works to reduce the psychiatric effects of autoimmunity.
For all panels of Figure 5, the growth rate was fixed to α = 0.01. Figure 5a shows that, when
no medication was administered (M = 0), the trajectories increased indefinitely along an invariant
direction, so there could be no stable state. When medication was increased to M = 3, the system
locally stabilized, so the effects of autoimmunity were at least temporarily counteracted (Figure
5b). When medication was increased over a certain threshold, the neurotoxic effect of cortisol
prevailed over its immunosuppressive effect, and the system became again unstable. This is shown
in Figure 5c, where the medication has been increased to M = 4.165, which was too high for the
respective antibody growth.
Figure 5: In all three panels, we fixed: µ1 = 2, µ2 = 2, k1 = 2, k2 = 2, k3 = 1, α1 = 1, a1 = a2 = 1,
ξ = 2, I = 1, α = 0.01. A. M = 0; the trajectories are attracted to a point. B. M = 3; the
trajectories are attracted to a cycle. C. M = 4.165; the trajectories are repelled.
Figures 6a and 6b illustrate the same phenomena for a slightly higher growth rate α = 0.05.
The medication M = 3, which was sufficient to stabilize a system with α = 0.01, is no longer
sufficient, and the dose has to be increased up to M = 6 to regain stability. A slightly larger dose,
however, would be again no longer useful (not shown).
It seems that for very large growth rates, this critical range in which medication stabilizes the
system disappears. This is suggested in Figure 6c: for α = 0.1, the medication has been increased
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Figure 6: In all three panels, we fixed: µ1 = 2, µ2 = 2, k1 = 2, k2 = 2, k3 = 1, α1 = 1, a1 = a2 = 1,
ξ = 2, I = 1. A. α = 0.05, M = 3; the trajectories are repelled. B. α = 0.05, M = 6. The
attractor is recovered. C. α = 0.1, M = 15. The trajectories can’t be forced to converge even with
very large values of M .
up to M = 15, with no beneficial effect on the system’s behavior at any intermediate stage.
We finally noted that, unlike in the original model (Figure 3), in the extended model decreasing
ξ does not force the trajectories to converge (not shown). In other words: while a lower drive of
the dopamine systems had a stabilizing effect in the simplified model, in the extended model a
similar decrement in dopamine modulation could not compensate for the effects of dysregulated
autoimmunity. On the other hand, a slight increase in cortisol levels seems to do that successfully, as
long as the dysregulation is not excessively pronounced. In the Discussion section, we offer a more
detailed explanation of this phenomenon within the context of antipsychotic and immunosuppresant
medication.
4 Discussion
Our model shows how a brain network involved in emotional processing, fear conditioning and
extinction can switch from normal to dysregulated behavior when certain functional parameters
are changed. More importantly, our paradigm shows how seemingly similar signs of dysregulation
could correspond to malfunction of totally different parameters, i.e., they could be manifestations
of totally different types of physiological impairment. This goes hand in hand with our hypothesis
of multiple etiologies of psychosis, as described in the Introduction section. We would therefore
like to interpret here more thoroughly our results that support this idea.
In our previous two-dimensional approach [48], we have already discussed some of the effects
of perturbing the amygdalar self-inhibition µ1 and the cortisol vulnerability coefficients a1 and
a2. While we associated the linear coefficient with the individual’s trait anxiety, the vulnerability
parameter reflected the degree of the nonlinearity, which we believe to be the key determinator of
the disease process. Our new computations confirm and extend these prior results. The loss of
stability with the decrease of amygdalar self-inhibition reaffirms the importance of this inhibition
in maintaining a well-regulated limbic-prefrontal system. Lack of proper such inhibition may lead
to a less efficient return to baseline after a stressor. On the other hand, a dysregulation in the
inhibitory feedback loop produced by increased vulnerability to stress (larger a1 or a2) may cause
time evolutions to never converge, thus leading to ranges of brain activations compatible with
psychotic behavior [48].
As an extension of this paradigm, we introduced here explicitly the effects of the dopamine mod-
ules, which are known to be very important in the genesis of psychosis. We observed that an increase
in the dopaminergic modulation could produce a dysregulation in the system’s evolution which is
almost indistinguishable from an increase in vulnerability to cortisol. This effect corresponds to
the well-known fact (which lies at the very basis of the pharmacology of antipsychotics [4]) that
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dopamine antagonists alleviate (without definitively curing) psychotic symptoms. In the same direc-
tion, we also noted that a dysregulation in our system caused by increased prefrontal/hippocampal
cortisol vulnerability can be compensated by decreasing the dopamine responsiveness, i.e., by ad-
ministration of dopamine antagonist medication. This is also in full accordance with the theory of
existing medical treatment for schizophrenia.
The rest of the discussion will focus on the impact of autoimmunity. The game of autoimmune
regulation is governed by the exponential growth rate of the autoantibody production. This rate
can be effectively decreased by boosting the blood cortisol levels, e.g. by administration of corti-
costeroids. This slows down the exponential growth and implicitly lowers the detrimental effects of
the antibodies on the brain. The corticosteroid treatment of defective autoimmunity works only to
some degree, since an excess of cortisol can push the system into the opposite range of instability,
due to hypercortisolemia. Indeed, recent studies have revealed that psychosis in SLE can appear as
a secondary effect of medication, and that this psychosis is clinically indistinguishable from primary
SLE psychosis [10].
In general, however, corticosteroid medication works well if administered correctly in SLE [57].
A very important message of our model is that, in the case of an actual autoimmune disorder,
antipsychotics can’t be regarded as a substitute or alternative to immunosuppressants. This em-
phasizes once more the importance of teasing apart the different mechanisms underlying psychosis,
and of assigning medication customized to fit the particular corresponding malfunction. In our
case, misdiagnosing SLE as schizophrenia, which probably happens more often than we know [3],
would lead to administering classical antipsychotic medication to a person suffering of an autoim-
mune condition. This is very ineffective, and detrimental to health, given the side effects of all
antipsychotics. (Note on linguistics: To be able to express some distinctions, we confine ourselves
here to refer to “schizophrenia” in its classical sense of stress/vulnerability condition.) Fortunately,
the reciprocal mistake of misdiagnosing schizophrenia as SLE does not happen that often, since
SLE usually comes with more identifiable, nonpsychiatric signs and symptoms. The consequences
of such a misdiagnosis would have been even more dire, since corticosteroid medication assigned to
a person with a vulnerability to cortisol would readily enhance the already manifest psychosis.
Finally, this mechanism provides a good example of an instance where two different drugs
administered to patients with similar outward symptoms, may achieve a similar clinical outcome.
This is not the only psychiatric context in which such questions have been raised. A more elaborate
model could perhaps encompass other such phenomena, such as the similar effects that dopamine
agonists and dopamine antagonists seem to have as treatment to certain psychotic symptoms [62].
5 Limitations and future work
5.1 The limits and advantages of modeling
One specific problem that has been pointed out in both our previous and current paradigms is that
the psychotic symptoms we describe and model are not necessarily specific to schizophrenia, and
could be considered common to other conditions of emotional dysregulation of the brain. However,
this problem is more of a linguistic tautology, since it is the psychiatric diagnostic itself that we
are challenging.
A more serious drawback comes from the fact that the physiology described by models such
as ours can only capture a simplified and approximate picture. At this point in psychiatric re-
search, modeling cannot be considered the final answer, but rather only a step towards a better
understanding of the problem and its complexity. Clearly, there can always be a better model.
However, a more elaborate model would need to be supported with more precise physiological
information. In this context, the state of the current experimental data is at a crossroads. Take
for instance our paradigm of immunity-based psychosis. On one hand, research of both physiology
of mental illness and autoimmunity mechanisms has accomplished great progress in the past few
decades. On the other hand, knowledge of both autoimmunity and schizophrenia — specifically
that of antibodies against brain structures of neurons and glial cells — is still controversial. The
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first steps to understanding how antigen-antibody pathology might play in mental illness has been
established by animal research [69], which is debatably relevant to human pathophysiology. In
clinical research, while some found serum antibrain antibodies in 28-95% of studied schizophren-
ics [32] [18] [12] [25], others were unable to reproduce these findings [52] [37] [16].
We suggest that this quandary can be solved only as experimental research comes together with
the model theoretical and computational efforts, completing and validating each other, to produce
a stronger hypothesis of the mechanisms that govern autoimmunity and mental illness. Indeed,
psychiatric modeling is a science that should evolve interactively with the progress in experimental
methods. New techniques of measuring physiological parameters such as brain activation (fMRI,
NIRS, MEG) or autoimmunity [51] [17] offer better suited means of experimental investigation.
In some contexts (such as autoimmune dysregulation and its psychiatric effects), these techniques
have not yet been exploited at their fullest [10].
Such methods have spurred a new culture of parameter-identification and other techniques
of quantitative evaluation from data (such as Dynamic Causal Modeling [30], or computation of
dynamical invariants [50]). These are appropriate to be used and should be used to create and
validate more realistic theoretical models .
5.2 The future of diagnosis
Based on the novel quantitative approaches to psychophysiology and psychopathology, one concept
which has recently started to gain ground is temporal architecture profiling [48] [46]. Profiling
could complement, perhaps even totally eliminate the current diagnosis assignment, which is not
only unreliable and incompatible with multiple etiologies, but also socially undesirable and stig-
matizing. This could finally mean assembling a quantitative assessment toolbox for schizophrenia.
The dynamical “brain profile” of a particular patient or high risk individual could be created —
possibly from a set of clinically measurable parameters — describing physiological features such as
brain interactions, or stress vulnerability. This profile could then be compared against a multidi-
mensional, continuous profile chart, constructed based on common statistics. The individual would
thus be placed in the right locus of risk/vulnerability, which would facilitate predictions and help
assign the most appropriate treatment.
Such theories have already started to emerge in psychiatric literature. Peled [46], for example,
proposes a brain profiling chart based on three dimensions: neural complexity disorders, neuronal
resilience insufficiency and context-sensitive processing decline. Relevant equations would be used
to calculate and normalize the different values attributed to relevant brain disturbances. The first
dimension relates to disturbances occurring to fast neuronal activations and incorporates connectiv-
ity and hierarchical imbalances. The second dimension relates to disturbances that alter long-term
synaptic modulations, and incorporates disturbances to optimization within neuronal circuitry.
Finally the third dimension refers to the level of internal representations.
In the same direction of thinking, our previous work suggests an example of rudimentary pro-
filing based on two dimensions: the amygdalar self-inhibition µ1 and the level of nonlinearity of
the prefrontal-limbic system, measured by the Lyapunov number σ [48]. Our current model sug-
gests that a better classification could be obtained from considering a multi-dimensional profile, for
example in the parameter space (µ1, a1, a2, ξ, β).
This view of psychiatric diagnosis is still in its cradle, but it offers great promise and testable
predictions about the etiology of mental disorders. It studies are time trajectories, which intrin-
sically encompass the clinical history of the patient. It is also brain-related, so it relies on brain
imaging investigations which are much more precise than behavioral assessments. In short, brain
profiling diagnosis could be a bold new step towards a reformed psychiatry.
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